The purpose of this research study is to interview patients with fatty liver disease who are planning to have liver surgery. Our goal is to understand patients' health beliefs with fatty liver disease and what weight loss behaviors they would be willing to follow prior to surgery. You are being asked to be in the study because you are a patient with fatty liver disease planning to have liver surgery.

The purpose of this study is to understand how body fat and skeletal muscle in your body impacts your heart, kidney, and metabolic health. This research may help to better diagnose and treat patients and prevent progression of cardiovascular-kidney-metabolic diseases.

The purpose of this research study is to monitor how well patients with fatty liver disease can follow clinician-recommended diet and exercise before their liver surgery. Our goal is to understand patient adherence to weight-related goals, weight loss, physical activity, and improved liver health. You are being asked to be in the study because you are a patient with fatty liver disease planning to have liver surgery.

This research is studying the JuxtaFlow® Renal Assist Device (JuxtaFlow® RAD), to determine whether it enhances kidney function in patients with kidney function problems who are having a heart operation that requires a heart-lung machine. This device is investigational, which means it is not approved by the (Food and Drug Administration) FDA. However, the FDA or regulatory body has approved the clinical use of this device in this research study.

The purpose of this study is to gauge interest in a peer support program to help individuals with chronic kidney disease who are pregnant or are contemplating pregnancy navigate decision-making and care management. This survey will help us understand patients' desires for such a program and ways it can be implemented to best serve their needs and preferences.

Liver injury due to prescription and non-prescription medication is medical, scientific, and public health problem of increasing frequency and importance in United States. Drug-induced liver injury (DILI) is the most common reason the Food and Drug Administration (FDA) would choose not to approve a new drug or withdraw a drug from the market. However, drug-induced liver injuries are often under-reported and difficult to detect/diagnose. This study seeks to learn more about these drug-induced liver injuries and develop better ways to detect, define, and study drug-induced liver injuries. The study will be looking at new cases of drug-induced liver injury, as well as gathering data on previous drug-induced liver injury (up to January 1, 1994).

To collect quantitative data to: -Primarily gain a better understanding of patients' attitudes and preferences regarding end-of-life care management if they were to develop a high-risk skin cancer. To be more specific, we hope to gain a better understanding of how patients weigh their risk of developing skin cancer while taking immunosuppressants versus the risk of transplant rejection should they choose to stop or lower their immunosuppressants. -Determine how far these kidney transplant recipients travel to obtain skin-related care -Determine how frequently kidney transplant recipients obtain skin exams -Determine patients' baseline knowledge regarding risk of skin cancer while taking immunosuppressants, which are medicines that lowers immune systems -Determine the quality of life of individuals with skin cancer who are kidney transplant recipients

Infections occurring in individuals with glomerular disease are preventable contributors to excess healthcare utilization, morbidity, and mortality, and are the leading cause of death in children with glomerular disease. Vaccination is a powerful and cost-effective method to attenuate infectious burden, and clinical guidelines recommend that patients with glomerular disease receive 23-valent pneumococcal (PPSV23) vaccine. The main objective of the study is to determine functional PPSV23 immunogenicity in a prospectively collected multicenter cohort of children with idiopathic nephrotic syndrome using measurements of anti-pneumococcal and opsonophagocytic antibody titers prior to, and 1, 3 and 12 months following PPSV23 vaccination.

We have created this registry to provide an opportunity to study diagnostic capabilities, administration protocols and long-term effects of contrast-enhanced ultrasound (CEUS) of any organ.

We are collecting data on children living with chronic kidney disease, including children on dialysis or with a kidney transplant, to learn more about what happens over time. The data collected will be used for research projects.